Epidermolysis Bullosa News writes about InMed’s Phase 2 clinical trial of INM-755 cannabinol cream, an investigational new treatment for epidermolysis bullosa.
Excerpt:
INM-755 was found to be safe in five adults with epidermolysis bullosa (EB) who were treated with the investigational cannabinol cream in a Phase 2 trial.
The safety data led an independent data monitoring committee to agree that it is safe to enroll adolescents, ages 12–17, in the trial. The first adolescent patient has been enrolled and completed treatment at a clinical site in Greece, the therapy’s developer, InMed Pharmaceuticals, announced.
Full article here
